AIPM welcomes the new member: the international pharmaceutical company CSL Behring has become a member of the Association

“We feel proud to note that every year AIPM expands its membership by accepting pharmaceutical companies with innovative product portfolios, including biotechnological medicines, manufacturing sites and R&D centers of which are located in different parts of the world. And now we are pleased to announce the election of CSL Behring company, one of the recognized world leaders in the market of therapy with blood plasma medicines, as AIPM member. Today the Association is a unique platform performing highly professional expertise in the field of healthcare and circulation of medicines, and each new member of our team brings to our activities additional knowledge, competences, best corporate practices and business culture, contributing to the realization of honorable and responsible mission - work for the benefit of the health of our country’s population”, said Vladimir Shipkov, AIPM Executive Director.

“The history of CSL Behring dates back to the beginning of the 20th century, when E. Behring, the company's future founder, became the first Nobel Prize winner for physiology and medicine. And now, during more than 100 years the company has been developing and manufacturing highly effective biopharmaceuticals used to treat rare, serious diseases, such as, for example, hemophilia and various immunodeficiencies. Being manufacturers we also realize that our lasting more than a century responsibility to the community and patients always goes beyond simple developing of new drugs and treatments. Joining AIPM we confidently believe that entering such an expert community will help us to increase involvement in the regulation of the pharmaceutical market, take an active part in community life and direct our consolidated efforts more effectively to increase the availability of health care and the quality of life of patients in Russia. We are driven by our promise,”- said Ms. Maria Lituchaya, Head of the Branch of CSL Behring Biotherapies GmbH in Russia.

Reference:

CSL is a leading global biopharmaceutical company with a dynamic portfolio of life-saving innovative drugs and vaccines. Founded more than 100 years ago, today the CSL group is represented by two main divisions: CSL Behring and Seqirus. It operates in more than 30 countries of the world, its staff includes more than 14,000 people. CSL Behring is the world leader in biotechnology and plasma derived products, develops and offers a wide range of drugs for the treatment of hemophilia, von Willebrand disease, primary immunodeficiency and others. CSL Behring medications are also used in cardiac surgery, organ transplants and for the treatment of serious burns. The CSL Group also owns and operates one of the world's largest blood plasma collection networks – CSL Plasma, which includes 130 centers in the US and Europe. Over the past year the company has opened 22 new centers and plans further expansion of the network.

For more information please refer to: www.cslbehring.com

The Association of International Pharmaceutical Manufacturers (AIPM) brings together 60 international companies, which account for over 80% of world pharmaceutical production and more than 60% of the volume of medicines supplied to the Russian Federation.

www.aipm.org

For additional information, please contact

Irina Sheykkha, Legal and Communications Director, AIPM
+7 (495) 933 70 40
I.Sheykkha@aipm.org